Floatz Rating
C34/100
Confidence
Indicative
Sponsor
Peking Union Medical College Hospital
Modality
radiopharmaceutical
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05603559CT.gov 177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Prostate Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 177lu-p17-088 (this asset) | Peking Union Medical College Hospital | Early P1 | C · 34 |
| Prednisone | Mayo Clinic | P4 | BBB |
| Abiraterone | Mayo Clinic | P4 | BB |
| Cabazitaxel | AstraZeneca | P4 | BB |
| AXUMIN | VA Greater Los Angeles Healthcare System | P4 | BB |
| Enzalutamide | AstraZeneca | P4 | BB |
| Leuporelin | Mayo Clinic | P4 | BB |
| Prednisolone | BioNTech SE | P4 | BB |
| Degarelix | Praful Ravi, MB BCHir, MRCP | P3 | BB |
+42 more in the Metastatic Prostate Carcinoma cohort
Other indications for 177lu-p17-088
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Cancer | — | P2 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. 177lu-p17-088 in Metastatic Prostate Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/177lu-p17-088-metastatic-prostate-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →